

****New release July 2012****

MarketVIEW: Hepatitis A vaccines (Emerging/ROW) (CAT: VAMV029)

Product Name	:	MarketVIEW: Hepatitis A vaccines (Emerging/ROW)
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation + 1 forecast model
Therapeutic Area	:	Pediatric/adults vaccines
Publication date	:	July 2012
Catalogue No	:	VAMV029

Background

Hepatitis A (HAV) produces a self-limiting liver disease which can produce a range of symptoms such as nausea, anorexia, fever, malaise or abdominal pain. Unlike Hepatitis B and C viruses it does not cause a long term chronic infection although it can manifest itself as prolonged or relapsing disease for up to six months. The HAV virus is transmitted by person-to-person transmission through the fecal-oral route sometimes in outbreaks to due ingestion of contaminated food. Many countries in Africa, LATAM and SE Asia have high or intermediate endemicity for HAV.

The Hepatitis A vaccine is highly effective at preventing HAV infection and is now recommended for all children at age 1 year in the United States and other selected countries which have added the vaccine as part of a national immunization program (NIP). The HAV vaccine is also widely used in the travelling population to high or intermediate endemic countries.

This **MarketVIEW** product is a comprehensive commercial opportunity assessment which forecasts the potential (value/volume) of HAV vaccines in 35 countries in the “Emerging” or Rest of World region (ROW) to 2030. The model takes into account expected new NIPs, probable “catch-up” campaigns and expansion of private sector use in selected age groups. A detailed executive presentation is also included outlining all model outputs, assumptions and a country-by-country review of epidemiological dynamics and vaccination policy.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to hepatitis A virus epidemiology/vaccines. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of pediatric vaccines has also been utilised. *****See Bibliography for exact sources.**

PRODUCT CONTENTS:

Published July 2012 (CAT No: VAMV029)

****This product is composed a forecast model and an Executive presentation

Contents – Executive presentation (MS PowerPoint based)

Author's note
Executive summary
Commercial model – key outputs
HAV monovalent vaccine(s): available market (€ 000s) to 2030
HAV monovalent vaccine(s): available volume (€ 000s) to 2030
HAV monovalent vaccine(s): BRIC-MT markets (€ 000s) to 2030
HAV monovalent vaccine(s): BRIC-MT volume (000s) to 2030
HAV monovalent vaccine(s): available market(s) (€ 000s) to 2030
Hepatitis A virus: Review of current epidemiology
Global epidemiology: seroprevalence
Global epidemiology: seroprevalence (cont..)
Global epidemiology: incidence
US: incidence
Europe: incidence
5EU overview: incidence
Other high-income countries: incidence
Trends in incidence rates (low endemicity countries)
BRIC-M: incidence
Other LATAM: epidemiology
Southeast Asia overview
Hong Kong
Singapore
Taiwan
Malaysia
Philippines
Thailand
South Korea
Mongolia
Nepal
HAV epidemiology summary
Hepatitis A virus vaccines: Key model assumptions
Populations modelled
Overview of modeling strategy: new infant NIPs
Overview of modeling strategy: private adult segment
Overview of modeling strategy: at risk population
National HAV vaccine policies



Continued.....

Coverage rates
Populations modelled: at risk population
Commercial model assumptions: Infant, public
Commercial model assumptions: Infant, public (cont..)
Bibliography
Disclaimer
About **VacZine Analytics**

PAGES: 65 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based)

Title sheet
Notes
CHARTS – VALUE (total)
CHARTS – VOLUME (total)
WPR summary
Country value summary (Total)
Public vs private value summary
Value adult (priv)
Value infant (priv)
Value preschool (priv)
Value infant (pub)
Value adult (pub)
Global price summary
Volume adult (priv)
Volume infant (priv)
Volume preschool (priv)
Volume infant (pub)
Volume adult (pub)
Country worksheets
China (infants)
S Korea (infants)
Israel (infants)
Australia (infants)
Argentina (infants)
Panama (infants)
Paraguay (infants)
Uruguay (infants)
Taiwan (infants)
Russia (infants)
Kazakhstan (infants)
India (infants)
Ukraine (infants)
Brazil (infants)
Turkey (infants)
Mexico (infants)
Peru (infants)
Venezuela (infants)
Columbia (infants)
Chile (infants)
Guatemala (infants)
Saudi Arabia (infants)



Continued.....

Other Middle East (infants)
Belarus (infants)
Hong Kong (infants)
Malaysia (infants)
Thailand (infants)
Vietnam (infants)
Nepal (infants)
Pakistan (infants)
Philippines (infants)
Mongolia (infants)
Pakistan (infants)
Pakistan (infants)
Pakistan (infants)
Japan (infants)
Sheets repeated for adults, preschoolers
Population databases
Scenarios
"at risk" populations
Urban populations
% private
HBV coverage: case studies
Epidemiology
Income groups
World Population
Back page

WORKSHEETS = 110

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD \$8995.00/ GBP £6000.00[#] (Region license)*

*A region is North America, Europe or ROW


For orders in the UK, VAT at 20% will be added to final invoice total

indicative only rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

1. Jacobsen KH et al. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. *Vaccine*. 2010 Sep 24;28(41):6653-7.
2. World Health Organization. The global prevalence of hepatitis A virus infection and susceptibility : a systematic review.. Dept. of Immunization, Vaccines and Biologicals. 2010.
3. US Centers for Disease Control and Prevention. Viral Hepatitis Statistics and Surveillance. National Notifiable Diseases Surveillance System, 1966-2008. Available at: <http://www.cdc.gov/hepatitis/Statistics/2008Surveillance/Table1a.htm>. Accessed July 2011
4. Agency for Healthcare Research and Quality. HCUPnet. Available at: <http://hcupnet.ahrq.gov/>. Accessed: July 2011.
5. Annual epidemiological report on communicable diseases in Europe. 2010. European Centre For Disease Control. Available at: http://ecdc.europa.eu/en/publications/Publications/1011_SUR_Annual_Epidemiological_Report_on_Communicable_Diseases_in_Europe.pdf. Accessed July 2011.
6. Hepatitis A Laboratory Reports and Statutory Notifications, England and Wales. Available at: <http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HepatitisA/EpidemiologicalData/>. Accessed: July 2011.
7. Gastro-intestinal and foodborne infections: Incidence of viral and protozoal infections reported to HPS in 2010. Available at: <http://www.hps.scot.nhs.uk/ewr/article.aspx>. Accessed: July 2011.
8. Public Health Agency Hepatitis. Available at: <http://www.publichealth.hscni.net/directorate-public-health/hepatitis>. Accessed: July 2011.
9. Robert Koch-Institut. Available at: <http://www3.rki.de/SurvStat/QueryForm.aspx>. Accessed: July 2011.
10. Hépatite A. Données épidémiologiques. Available at: <http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-declaration-obligatoire/Hepatitis-A/Donnees-epidemiologiques>. Accessed: July 2011.
11. Infectious Disease Surveillance Center. Available at: <http://idsc.nih.gov/jp/>. Accessed: July 2011.
12. Notifiable Diseases On-Line. Available at: http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/c_ind-eng.php#top_list. Accessed: July 2011.
13. Australian Government. National Notifiable Disease Surveillance System. Available at: http://www9.health.gov.au/cda/Source/Rpt_2_sel.cfm. Accessed July 2011.
14. HEPATITES VIRALIS A - Confirmed Reported in Information System for Notifiable Diseases - Sinan Net. Available at: <http://dtr2004.saude.gov.br/sinanweb/index.php>. Accessed July 2011.
15. Letter from 04.03.2011 № 01/2390-1-32 Interaction of regional bodies and institutions with Rospotrebnadzor Reference Centre for Monitoring of viral hepatitis. Available at: <http://www.rospotrebnadzor.ru/>. Accessed: July 2011.
16. 2010 National Notifiable infectious diseases morbidity, mortality tables. Available at: www.gov.cn/gzdt/att/att/site1/20110212/00142235eb180ec0209202.doc. Accessed July 2011.
17. J Ruiz-gómez J. Hepatitis A virus infection among mexican young population. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. Miami, Florida, US, 30 November to 1 December 2007.
18. Mathur P et al. Epidemiological transition of hepatitis A in India: issues for vaccination in developing countries. *Indian J Med Res*. 2008 Dec;128(6):699-704
19. Rísquez A et al. Epidemiology of hepatitis A in Venezuela 1990-2005. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. Miami, Florida, US, 30 November to 1 December 2007.
20. Mariño AC et al. Seroprevalence of hepatitis A virus in Colombian children 1-15 years old. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. Miami, Florida, US, 30 November to 1 December 2007.
21. Abarca K. Hepatitis A Prevention In Chile. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. Miami, Florida, US, 30 November to 1 December 2007.
22. Refs within: World Health Organization. The global prevalence of hepatitis A virus infection and susceptibility: a systematic review. Dept. of Immunization, Vaccines and Biologicals. 2010.
23. Hong Kong Department of Health. Recommended Strategies on HAV Vaccination in Hong Kong. Available at: <http://www.info.gov.hk/hepatitis/doc/hk.pdf>. Accessed February 2012
24. Surveillance of Viral Hepatitis in Hong Kong – 2010 update report. Available at: <http://www.info.gov.hk/hepatitis/doc/hepsurv10.pdf>. Accessed February 2012
25. Scientific Committee on Enteric Infections and Foodborne diseases. Changing Epidemiology of Hepatitis A in Hong Kong and Implications on Control Strategies. Available at: <http://www.info.gov.hk/hepatitis/doc/hk.pdf>. Accessed February 2012
26. Chen JY et al. Changing Prevalence of Anti-Hepatitis A Virus in Adolescents in A Rural Township in Taiwan. *Chang Gung Med J* 2010; 33: 321-6
27. Taiwan CDC. Hepatitis Control Program Phase V. Available at: <http://www.cdc.gov.tw/public/Data/7121816285471.pdf>. Accessed February 2012
28. Tsou TP et al. Change in Hepatitis A epidemiology after vaccinating high risk children in Taiwan, 1995-2008. *Vaccine* 29 (2011) 2956-2961

29. Taiwan CDC. Current Immunization Schedule in Taiwan. Available at: <http://www.cdc.gov.tw/public/Data/031517593171.pdf>. Accessed February 2012
30. Lee CH et al. Changing epidemiological patterns of hepatitis A infection in Singapore. *Ann Acad Med Singapore* 2011; 40: 439-47
31. Ahmand F., et al. Anti-hepatitis A seroprevalence among chronic viral hepatitis patients in Kelantan, Malaysia. *World J Gastroenterol.* 2011 September 28; 17(36): 4130-4134.
32. Ministry of Health Malaysia. Clinical Practice Guidelines. Adult Vaccination, 2003. Available at: www.acadmed.org.my/view_file.cfm?fileid=184. Accessed February 2012
33. Ministry of Health Malaysia. Health Indicators 2009. Available at: http://www.moh.gov.my/images/gallery/publications/md/hi/hi_2009.pdf. Accessed February 2012
34. Barzaga NG et al. Seroepidemiology of Hepatitis A virus among Filipinos Living in Selected Communities In and Around Metro Manila. *Phil J Microbiol Infect Dis* 1996; 25(2):39-47
35. Ratanasuwan W et al. Serological survey of viral Hepatitis A, B and C at Thai central region and Bangkok: a population based study. *SE Asian J Trop Med Public Health.* Vol 35 No 2 June 2004
36. Soogarun S, Wiwanitkit V. Vaccinating Thai adolescents against hepatitis A: Is it costeffective? *Southeast Asian J Trop Med Public Health* 2002; 33 (Supl. 3): 145-8.
37. Wiwanitkit V. Hepatitis A Vaccination among Thai Medical Students: A questionnaire study. *Hepatitis Monthly* 2008; 8(2):151-152
38. Lee H et al. Seroepidemiology of Hepatitis A in Korea: Changes over the past 30 years. *J Korean Med Sci* 2011; 26: 791-796
39. Korean Center for Disease Control. Available at: <http://www.cdc.go.kr>. Accessed February 2012
40. Jeong SH. Current Status and vaccine introduction for hepatitis A virus infection in Korea. *Korean J Gastroenterol.* 2008 Jun; 51(6):331-7
41. National Center for Health Development, Ministry of Health of Mongolia, 2008. Health Indicators 2007. Ulaanbaatar: Ministry of Health.
42. Davaalkham D et al. Hepatitis A and E Virus infections among children in Mongolia. 2009 vol. 81 no. 2 248-251
43. Takahashi M et al. High prevalence of antibodies to hepatitis A and E viruses and viremia of hepatitis B, C, and D viruses among apparently healthy populations in Mongolia. *Clin Diagn Lab Immunol* 11: 392-398
44. Hepatitis A vaccines. WHO position paper. *WHO Weekly Epidemiological Record - No 5* 2000, 75, 37-44
45. ACIP. Prevention of hepatitis A through active or passive immunization. *MMWR Recomm Rep.* 2006 May 19;55(RR-7):1-23.
46. Smith, TW. American Sexual Behavior 2006: trends, socio-demographic differences, and risk behavior. GSS topical report no. 25. Chicago: NORC.
47. Lu PJ et al. Hepatitis A vaccination coverage among adults aged 18-49 years in the United States. *Vaccine.* 2009 Feb 25;27(9):1301-5.
48. CDC/NCHS, National Health Interview Survey, 2009. Available at: www.cdc.gov/vaccines/stats-surv/nhis/downloads/2009-nhis-tables.xls. Accessed: July 2011.
49. Mathers BM et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet.* 2008 Nov 15;372(9651):1733-45.
50. Gerlich M et al. Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002. *Eur J Epidemiol.* 2006;21(7):545-9.
51. Moiseeva, A. Hepatitis A Seroprevalence In different Age Groups In Kiev City, Ukraine. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. Miami, Florida, US, 30 November to 1 December 2007.
52. Central European Vaccination Advisory Group. Inoculum 1. Warsaw, 7-8 March 2005. <http://www.cevag.org/resources.php>
53. Moraes JC et Al. Hepatitis A Vaccination's Rates In Schoolchildren: Necessity For More Medical And Public Education About Risks And Benefits. Available At: www.kenes.com/epid09/abstracts/pdf/546.pdf. Accessed August 2011.
54. Wasley A et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. *J Infect Dis.* 2010 Jul 15;202(2):192-201.
55. Armstrong GL et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Ann Intern Med.* 2006 May 16;144(10):705-14.
56. Sherman M et al. Management of chronic hepatitis B: consensus guidelines. *Can J Gastroenterol.* 2007 Jun;21 Suppl C:5C-24C.
57. Epidemiology of Acute Hepatitis C Infection in Canada Results from the Enhanced Hepatitis Strain Surveillance System (EHSSS). www.phac-aspc.gc.ca/sti-its-surv-epi/pdf/epi_update-eng.pdf
58. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: ECDC; 2010.
59. Australian Government Department of Health and Ageing. National Hepatitis B Strategy 2010-2013.
60. Amin J et al. Hepatitis C prevalence--a nationwide serosurvey. *Commun Dis Intell.* 2004;28(4):517-21
61. Diseases and health problems in Japan. Available at: <http://factsanddetails.com/japan>. Accessed: July 2011

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com



VacZine Analytics®
Bringing life to vaccine strategy...

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009

Bringing life to vaccine strategy...

www.vacZine-analytics.com

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** info@vacZine-analytics.com